All In Biotech

Free tool

FAERS Monitor: Glycine 1.5% In Plastic Container

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018315 or its brand name (Glycine 1.5% In Plastic Container, Glycine). Reports on generic versions are filed under their own applications.

Reports

329

Serious

262

80% of reports

Hospitalization

142

Death reported

28

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective37
  • nausea29
  • pneumonia27
  • off label use26
  • fatigue25
  • condition aggravated24
  • rash23
  • insomnia22
  • status epilepticus22
  • stevens-johnson syndrome22
  • depressed level of consciousness21
  • sopor21
  • diarrhoea18
  • headache18
  • pain16

Reports by year received

View as table
YearReports
20051
20091
20102
20111
201210
201310
20145
201511
201618
201735
201838
201911
202024
202120
202232
202325
202438
202527
202620

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,830 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
status epilepticusSignal22124.883.32,576
soporSignal21101.567.11,988
stevens-johnson syndromeSignal2263.342.31,287
depressed level of consciousnessSignal2134.022.4640
pneumoniaSignal275.33.792
insomniaSignal225.33.573
condition aggravatedSignal245.03.475
rashSignal233.42.337
nauseaSignal292.31.722
fatigueSignal252.11.413
off label use261.91.311
headache181.81.26
drug ineffective371.81.313
diarrhoea181.81.16
pain161.71.04

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.